Market Overview

UPDATE: Oppenheimer Raised PT on Verastem Following Analyst Day


In a report published Friday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating on Verastem (NASDAQ: VSTM), but lowered the price target from $16.00 to $18.00.

In the report, Oppenheimer noted, “VSTM provided a more granular view of the cancer stem cell (CSC) platform/pipeline. Focus remains on FAK inhibitor, VS-6063, slated to begin a registration-directed ph.II mesothelioma trial this summer. We believe VS-6063 is a promising shot on goal in this indication, based on the supportive theoretical/preclinical evidence. We also maintain comfort with the study design, which is strategically adaptive. Management also elaborated on the FAK inhibitor franchise's potential outside mesothelioma and on the unique properties of PI3K/mTOR inhibitor, VS-5584, relative to drugs in these classes. We expect continued momentum in VSTM as the pipeline progresses, with three compounds reporting new ph.I data through 2014. We are increasing our PT to $18, from $16, reflecting an improved outlook on the pipeline.”

Verastem closed on Thursday at $17.29.

Latest Ratings for VSTM

May 2020H.C. WainwrightReiteratesBuy
Mar 2020H.C. WainwrightMaintainsBuy
Mar 2020Cantor FitzgeraldMaintainsOverweight

View More Analyst Ratings for VSTM
View the Latest Analyst Ratings


Related Articles (VSTM)

View Comments and Join the Discussion!

Posted-In: David Ferreiro OppenheimerAnalyst Color Price Target Analyst Ratings

Latest Ratings

CYTKHC Wainwright & Co.Maintains38.0
COLLBWS FinancialInitiates Coverage On8.0
BFYTCanaccord GenuityDowngrades31.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at